Latest

3 stories

Hide weekly roundups

Wednesday, September 23

Eledon registers Phase 3 trial comparing tegoprubart with tacrolimus in kidney transplant

Trial updateEledon Pharmaceuticals tacrolimus

Thursday, August 13

Quarterly updateEledon Pharmaceuticals tegoprubart

Eledon reports Q2 2026 results, confirms Phase 3 kidney transplant trial on track for late 2026

Eledon said an End-of-Phase 2 FDA meeting cleared the path for a global Phase 3 trial of tegoprubart in kidney transplantation, while cash fell to $88.8 million.

SEC filing

Friday, July 31

FinancingNewcelX Ltd.

NewcelX prices $1.4 million private placement at 20% premium

The Zurich-based biopharmaceutical company will sell shares and warrants to fund its lead type 1 diabetes program after a recent FDA Pre-IND meeting.

SEC filing